FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023418900> ?p ?o ?g. }

• W2023418900 endingPage "39438" @default.
• W2023418900 startingPage "39431" @default.
• W2023418900 abstract "Congenital disorders of glycosylation (CDG) are rare genetic disorders due to impaired glycosylation. The patients with subtypes CDG-Ia and CDG-Ib have mutations in the genes encoding phosphomannomutase 2 (PMM2) and phosphomannose isomerase (MPI or PMI), respectively. PMM2 (mannose 6-phosphate → mannose 1-phosphate) and MPI (mannose 6-phosphate ⇔ fructose 6-phosphate) deficiencies reduce the metabolic flux of mannose 6-phosphate (Man-6-P) into glycosylation, resulting in unoccupied N-glycosylation sites. Both PMM2 and MPI compete for the same substrate, Man-6-P. Daily mannose doses reverse most of the symptoms of MPI-deficient CDG-Ib patients. However, CDG-Ia patients do not benefit from mannose supplementation because >95% Man-6-P is catabolized by MPI. We hypothesized that inhibiting MPI enzymatic activity would provide more Man-6-P for glycosylation and possibly benefit CDG-Ia patients with residual PMM2 activity. Here we show that MLS0315771, a potent MPI inhibitor from the benzoisothiazolone series, diverts Man-6-P toward glycosylation in various cell lines including fibroblasts from CDG-Ia patients and improves N-glycosylation. Finally, we show that MLS0315771 increases mannose metabolic flux toward glycosylation in zebrafish embryos. Congenital disorders of glycosylation (CDG) are rare genetic disorders due to impaired glycosylation. The patients with subtypes CDG-Ia and CDG-Ib have mutations in the genes encoding phosphomannomutase 2 (PMM2) and phosphomannose isomerase (MPI or PMI), respectively. PMM2 (mannose 6-phosphate → mannose 1-phosphate) and MPI (mannose 6-phosphate ⇔ fructose 6-phosphate) deficiencies reduce the metabolic flux of mannose 6-phosphate (Man-6-P) into glycosylation, resulting in unoccupied N-glycosylation sites. Both PMM2 and MPI compete for the same substrate, Man-6-P. Daily mannose doses reverse most of the symptoms of MPI-deficient CDG-Ib patients. However, CDG-Ia patients do not benefit from mannose supplementation because >95% Man-6-P is catabolized by MPI. We hypothesized that inhibiting MPI enzymatic activity would provide more Man-6-P for glycosylation and possibly benefit CDG-Ia patients with residual PMM2 activity. Here we show that MLS0315771, a potent MPI inhibitor from the benzoisothiazolone series, diverts Man-6-P toward glycosylation in various cell lines including fibroblasts from CDG-Ia patients and improves N-glycosylation. Finally, we show that MLS0315771 increases mannose metabolic flux toward glycosylation in zebrafish embryos. Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.Journal of Biological ChemistryVol. 286Issue 50PreviewVOLUME 286 (2011) PAGES 39431–39438 Full-Text PDF Open Access" @default.
• W2023418900 created "2016-06-24" @default.
• W2023418900 creator A5003549179 @default.
• W2023418900 creator A5008199007 @default.
• W2023418900 creator A5010143904 @default.
• W2023418900 creator A5021045099 @default.
• W2023418900 creator A5022953027 @default.
• W2023418900 creator A5026885060 @default.
• W2023418900 creator A5039016268 @default.
• W2023418900 creator A5063846120 @default.
• W2023418900 creator A5070670275 @default.
• W2023418900 date "2011-11-01" @default.
• W2023418900 modified "2023-10-18" @default.
• W2023418900 title "Phosphomannose Isomerase Inhibitors Improve N-Glycosylation in Selected Phosphomannomutase-deficient Fibroblasts" @default.
• W2023418900 cites W1527068991 @default.
• W2023418900 cites W1638153393 @default.
• W2023418900 cites W1666389017 @default.
• W2023418900 cites W1970122244 @default.
• W2023418900 cites W1988142527 @default.
• W2023418900 cites W1999425810 @default.
• W2023418900 cites W2002732932 @default.
• W2023418900 cites W2003888853 @default.
• W2023418900 cites W2007236926 @default.
• W2023418900 cites W2010734055 @default.
• W2023418900 cites W2015514724 @default.
• W2023418900 cites W2021441279 @default.
• W2023418900 cites W2027088487 @default.
• W2023418900 cites W2027805537 @default.
• W2023418900 cites W2036656454 @default.
• W2023418900 cites W2036810334 @default.
• W2023418900 cites W2075341764 @default.
• W2023418900 cites W2093313547 @default.
• W2023418900 cites W2101295178 @default.
• W2023418900 cites W2110418789 @default.
• W2023418900 cites W2118387878 @default.
• W2023418900 cites W2120010534 @default.
• W2023418900 cites W2131131384 @default.
• W2023418900 cites W2144665840 @default.
• W2023418900 cites W2146458937 @default.
• W2023418900 cites W2324733870 @default.
• W2023418900 cites W238923612 @default.
• W2023418900 cites W4252701774 @default.
• W2023418900 cites W4367436794 @default.
• W2023418900 doi "https://doi.org/10.1074/jbc.m111.285502" @default.
• W2023418900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3234810" @default.
• W2023418900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21949237" @default.
• W2023418900 hasPublicationYear "2011" @default.
• W2023418900 type Work @default.
• W2023418900 sameAs 2023418900 @default.
• W2023418900 citedByCount "39" @default.
• W2023418900 countsByYear W20234189002012 @default.
• W2023418900 countsByYear W20234189002013 @default.
• W2023418900 countsByYear W20234189002014 @default.
• W2023418900 countsByYear W20234189002015 @default.
• W2023418900 countsByYear W20234189002016 @default.
• W2023418900 countsByYear W20234189002017 @default.
• W2023418900 countsByYear W20234189002018 @default.
• W2023418900 countsByYear W20234189002019 @default.
• W2023418900 countsByYear W20234189002020 @default.
• W2023418900 countsByYear W20234189002021 @default.
• W2023418900 countsByYear W20234189002022 @default.
• W2023418900 countsByYear W20234189002023 @default.
• W2023418900 crossrefType "journal-article" @default.
• W2023418900 hasAuthorship W2023418900A5003549179 @default.
• W2023418900 hasAuthorship W2023418900A5008199007 @default.
• W2023418900 hasAuthorship W2023418900A5010143904 @default.
• W2023418900 hasAuthorship W2023418900A5021045099 @default.
• W2023418900 hasAuthorship W2023418900A5022953027 @default.
• W2023418900 hasAuthorship W2023418900A5026885060 @default.
• W2023418900 hasAuthorship W2023418900A5039016268 @default.
• W2023418900 hasAuthorship W2023418900A5063846120 @default.
• W2023418900 hasAuthorship W2023418900A5070670275 @default.
• W2023418900 hasBestOaLocation W20234189001 @default.
• W2023418900 hasConcept C108625454 @default.
• W2023418900 hasConcept C181199279 @default.
• W2023418900 hasConcept C185592680 @default.
• W2023418900 hasConcept C206212055 @default.
• W2023418900 hasConcept C2775887612 @default.
• W2023418900 hasConcept C2777313579 @default.
• W2023418900 hasConcept C2781264208 @default.
• W2023418900 hasConcept C30324644 @default.
• W2023418900 hasConcept C55493867 @default.
• W2023418900 hasConcept C86803240 @default.
• W2023418900 hasConceptScore W2023418900C108625454 @default.
• W2023418900 hasConceptScore W2023418900C181199279 @default.
• W2023418900 hasConceptScore W2023418900C185592680 @default.
• W2023418900 hasConceptScore W2023418900C206212055 @default.
• W2023418900 hasConceptScore W2023418900C2775887612 @default.
• W2023418900 hasConceptScore W2023418900C2777313579 @default.
• W2023418900 hasConceptScore W2023418900C2781264208 @default.
• W2023418900 hasConceptScore W2023418900C30324644 @default.
• W2023418900 hasConceptScore W2023418900C55493867 @default.
• W2023418900 hasConceptScore W2023418900C86803240 @default.
• W2023418900 hasIssue "45" @default.
• W2023418900 hasLocation W20234189001 @default.
• W2023418900 hasLocation W20234189002 @default.
• W2023418900 hasLocation W20234189003 @default.
• W2023418900 hasLocation W20234189004 @default.

• next